Table 1.
Summary of nucleoporin interactions and LacO rim targeting. The nucleoporins tested by IF are shown below. The percentages show the amount of colocalization of an endogenous Nup with the LacI-Nup/LacO array, calculated as the percent of transfected cells showing colocalization (triplicate experiments, minimum N = 100 cells per condition). Targeting of the LacO array to the nuclear rim is also shown (last column), calculated as percent of transfected cells with the LacO focus at the rim. The negative control, LacI-CFP, recruited no endogenous nucleoporins to the LacO array and showed no rim targeting, indicating high specificity of the LacI-Nup/LacO system.
| LacI-tagged | Intra-complex interactions | Inter-complex interactions | Low or not recruited | Rim targeting | ||
|---|---|---|---|---|---|---|
| Nup133 | Nup160 (44%) | ELYS (62%) | Nup214 (23%) | Nup62 (5%) | Yes (57%) | |
| Nup85 (86%) | Nup53 (20%) | Nup98 (70%) | ||||
| Nup93 (21%) | Pom121(45%) | |||||
| |
|
mAb414 (18%) |
|
|
|
|
| Nup107 | Nup133 (94%) | ELYS (72%) | Nup62 (24%) | Sometimes (25%) | ||
| Nup160 (39%) | Nup93 (9%) | Pom121 (26%) | ||||
| |
Nup85 (88%) |
mAb414 (20%) |
|
|
|
|
| Nup153 | N/A | Nup133 (35%) | Nup93 (23%) | Yes (76%) | ||
| Nup160 (33%) | Nup214 (6%) | |||||
| Nup85 (58%) | Nup62 (56%) | |||||
| |
|
ELYS (65%) |
Nup98 (11%) |
|
|
|
| Nup53 (14%) | Pom121(31%) | |||||
| Nup50 | N/A | Nup133 (11%) | Nup62 (43%) | Nup160 (4%) | Sometimes (30%) | |
| Nup85 (32%) | mAb414(46%) | |||||
| ELYS (37%) | Nup98 (11%) | |||||
| Nup53 (6%) | Pom121(24%) | |||||
| |
|
Nup93 (28%) |
|
|
|
|
| Nup214 | Not tested | Nup133 (35%) | Nup62 (97%) | Nup53 (0%) | No (0%) | |
| ELYS (40%) | Nup98 (90%) | |||||
| |
|
mAb414 (100%) |
|
|
|
|
| Nup53 | Nup93 (67%) | ELYS (34%) | Nup133 (3%) | Nup62 (2%) | Sometimes (27%) | |
| |
|
|
|
mAb414 (3%) |
Pom121 (0%) |
|
| Nup155 | Nup53 (46%) | Pom121 (56%) | Nup133 (3%) | Nup62 (3%) | Sometimes (16%) | |
| Nup160 (5%) | Nup214 (5%) | |||||
| |
|
|
|
Nup93 (2%) |
Nup98 (2%) |
|
| sPom121 | N/A | Nup133 (8%) | Nup62 (89%) | Nup160 (0%) | No (1%) | |
| Nup85 (7%) | mAb414 (20% | Nup53 (2%) | ||||
| ELYS (14%) | Nup98 (72%) | |||||
| |
|
Nup93 (68%) |
|
|
|
|
| Nup58 | Nup62 (100%) | ELYS (13%) | Nup133 (3%) | Nup21 (1%) | No (1%) | |
| Pom121 (14%) | Nup160 (5%) | Nup98 (5%) | ||||
| |
|
|
|
Nup85 (2%) |
|
|
| mNup85 | ELYS (9%) | Nup133 (0%) | Nup98 (0%) | No (1%) | ||
| Nup160 (2%) | Pom121 (4%) | |||||
| |
|
|
|
Nup53 (0%) |
|
|
| Nup98 | Not tested | ELYS (16%) | Nup133 (2%) | mAb414 (4%) | No (1%) | |
| |
|
Nup62 (8%) |
|
Nup53 (0%) |
Nup214 (1%) |
|
| CFP | Nup133 (0%) | mAb414 (0%) | No (1%) | |||
| Nup160 (0%) | Nup62 (0%) | |||||
| Nup85 (0%) | Nup214 (0%) | |||||
| ELYS (0%) | Nup98 (0%) | |||||
| Nup53 (0%) | Pom121 (0%) | |||||
| Nup93 (0%) | Nup155 (0%) | |||||